Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07181109 · ClinicalTrials.gov registry record · Phase 3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
A Phase 3 study of Hypertension and High Risk Cardiovascular Disease, sponsored by Alnylam Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 11,000
- Enrollment target
- 20
- Study locations
NCT07181109: Recruiting Phase 3 study of Hypertension and High Risk Cardiovascular Disease, sponsored by Alnylam Pharmaceuticals.
NCT07181109 is a Phase 3 study of Hypertension and High Risk Cardiovascular Disease that is actively recruiting participants, run by Alnylam Pharmaceuticals. The registered enrollment target is 11,000 participants, above the 3,484-participant average among 470 other Hypertension trials with a reported enrollment target (216% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07181109, a Phase 3 study of Hypertension and High Risk Cardiovascular Disease, is actively recruiting participants, sponsored by Alnylam Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 11,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate whether zilebesiran versus placebo reduces the risk of cardiovascular (CV) death, nonfatal myocardial infarction (MI), nonfatal stroke, or heart failure (HF) events. This is an event-driven study that will continue until the targeted number of positively adjudicated primary endpoint clinical outcome events (COEs) have been reached.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Zilebesiran
Study Locations (20)
Arizona
- Clinical Trial Site - Chandler
- Clinical Trial Site - Gilbert
- Clinical Trial Site - Glendale
- Clinical Trial Site - Mesa
- Clinical Trial Site - Phoenix
- Clinical Trial Site - Phoenix
- Clinical Trial Site - Sun City West
- Clinical Trial Site - Tucson
- Clinical Trial Site - Tucson
California
- Clinical Trial Site - Beverly Hills
- Clinical Trial Site - Chula Vista
- Clinical Trial Site - Escondido
- Clinical Trial Site - Glendale
- Clinical Trial Site - Lancaster
- Clinical Trial Site - Long Beach
Alabama
- Clinical Trial Site - Huntsville
- Clinical Trial Site - Huntsville
- Clinical Trial Site - Sheffield
Arkansas
- Clinical Trial Site - Little Rock
- Clinical Trial Site - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11,000 participants |
| Start Date | 2025-09-22 |
| Est. Completion | 2030-09-30 |
| Phase | Phase 3 |
What NCT07181109 shows while recruiting
NCT07181109 is an interventional study that assigns participants to a tested intervention. Its 11,000 participants enrollment target places it among the larger protocols in the corpus, above the 3,484-participant average among 470 other Hypertension trials with a reported enrollment target (216% higher).
The record links to 3 conditions, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07181109 names 20 study sites across 4 states, led by Arizona, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT07181109 about?
NCT07181109 is a clinical study titled "Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease". The purpose of this study is to evaluate whether zilebesiran versus placebo reduces the risk of cardiovascular (CV) death, nonfatal myocardial infarction (MI), nonfatal stroke, or heart failure (HF) events. This is an event-driven study that will continue until the targeted number of positively adju...
What is the current status of trial NCT07181109?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 11,000 participants. The study started on 2025-09-22. Estimated completion is 2030-09-30.
What conditions does trial NCT07181109 study?
This clinical trial studies the following conditions: Hypertension, High Risk Cardiovascular Disease, High Cardiovascular Risk.
What interventions are being tested in trial NCT07181109?
The interventions under investigation include: Placebo (DRUG), Zilebesiran (DRUG).
Who is sponsoring clinical trial NCT07181109?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07181109 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07181109's enrollment target sits among peer trials
11,000 20th of 470 higher than 451 of 470 other Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
RECRUITING · Phase 3
-
Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06531824 · 11,000 participants · Phase 3
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
- NCT07136012 · 11,000 participants · Phase 3
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
- NCT06736951 · 10,890 participants · NA
Modifying the Inpatient Environment to Reduce Delirium in Older Adults
- NCT06468202 · 10,742 participants · Phase 4
Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI